Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ: VCYT )

31.60 +0.09 (+0.29%)
Streaming Delayed Price Updated: 12:50 PM EDT, Mar 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
From Veracyte, Inc.
Via Business Wire
Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022
From Veracyte, Inc.
Via Business Wire
New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men
From Veracyte, Inc.
Via Business Wire
Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access
From Veracyte, Inc.
Via Business Wire
New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer
From Veracyte, Inc.
Via Business Wire
New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy
From Veracyte, Inc.
Via Business Wire
Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From Veracyte, Inc.
Via Business Wire
Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022
From Veracyte, Inc.
Via Business Wire
New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma
From Veracyte, Inc.
Via Business Wire
Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors
From Veracyte, Inc.
Via Business Wire
Veracyte Announces Second Quarter 2022 Financial Results
From Veracyte, Inc.
Via Business Wire
Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid
From Veracyte, Inc.
Via Business Wire
Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022
From Veracyte, Inc.
Via Business Wire
New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis
From Veracyte, Inc.
Via Business Wire
Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year
From Veracyte, Inc.
Via Business Wire
New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice
From Veracyte, Inc.
Via Business Wire
Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression
From Veracyte, Inc.
Via Business Wire
Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer
From Veracyte, Inc.
Via Business Wire
New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier
From Veracyte, Inc.
Via Business Wire
Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors
From Veracyte, Inc.
Via Business Wire
Veracyte to Present at Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment
From Veracyte, Inc.
Via Business Wire
Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Veracyte Announces that Data for Its Genomic and Immuno-Oncology Offerings Will Be Highlighted at the 2022 ASCO Annual Meeting
From Veracyte
Via Business Wire
Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022
From Veracyte, Inc.
Via Business Wire
Veracyte Announces First Quarter 2022 Financial Results
From Veracyte, Inc.
Via Business Wire
Envisia Genomic Classifier Highlighted in Updated Clinical Practice Guideline Regarding Idiopathic Pulmonary Fibrosis Diagnosis
From Veracyte, Inc.
Via Business Wire
Veracyte Announces New Urologic Cancer Data To Be Presented at AUA 2022 International Conference
From Veracyte, Inc.
Via Business Wire
Veracyte Announces New Performance Data for the Percepta Nasal Swab Test To Be Presented at ATS 2022 International Conference
From Veracyte, Inc.
Via Business Wire
Veracyte to Release First Quarter 2022 Financial Results on May 3, 2022
From Veracyte, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.